What is CustoMED?
Founded in 2018, CustoMED operates as a surgeon-first platform dedicated to the advancement of AI-powered, patient-specific orthopedic surgery. Emerging from the Sheba Medical Center's 3D Printing & Innovation Lab, the company utilizes sophisticated AI-driven automation to translate complex surgical decisions into highly accurate, patient-tailored surgical guides and implants. This approach effectively bridges the gap between digital surgical planning and physical execution, significantly reducing intraoperative variability and improving patient outcomes.
The company's market position is defined by its deep integration into the clinical workflow, moving beyond generic medical devices to provide bespoke solutions that address the specific anatomical requirements of each patient. By automating the design process, CustoMED empowers surgeons to achieve higher levels of precision, positioning itself as a critical infrastructure provider in the modern operating room.
How much funding has CustoMED raised?
CustoMED has raised a total of $6M across 1 funding round:
Seed
$6M
Seed (2025): $6M with participation from Israel Innovation Authority, Longevity Venture Partners, and Varana Capital
Key Investors in CustoMED
Israel Innovation Authority
The Innovation Authority is responsible for driving, investing in, and developing Israel's technological innovation. It supports entrepreneurs, startups, large companies, researchers, and students with innovative ideas, helping them turn visions into reality.
Longevity Venture Partners
Longevity Venture Partners is an early-stage venture capital firm focused on supporting entrepreneurs in the Silvertech, Healthcare, and Wellness sectors.
Varana Capital
Varana Capital is a Denver-based investment firm specializing in pre-seed through series A technology investments, primarily focused on asset-light deep-tech.
What's next for CustoMED?
With the recent capital injection, CustoMED is set to scale its operational capacity and refine its proprietary AI algorithms. The strategic roadmap includes expanding the platform's compatibility with diverse orthopedic procedures and strengthening its regulatory and commercial presence in international markets. As the demand for personalized medicine continues to rise, CustoMED is well-positioned to lead the transition toward automated, data-informed surgical interventions.
The company will likely focus on deepening its partnerships with major hospital networks and medical device manufacturers to integrate its 3D printing workflows into standard clinical practice. By maintaining its focus on surgeon-centric design, CustoMED aims to set a new standard for efficiency and accuracy in orthopedic care, ensuring that its technological advancements translate into tangible improvements in long-term patient health.
